Cytokinetics is committed to our mission of developing potential medicines that may improve the healthspan of people living with cardiovascular and neuromuscular diseases of impaired muscle function.
Our excellence in execution in 2019 positioned us well for what could be a transformative year for our company. We remain mindful of the unmet needs facing patients with impaired muscle function and are motivated to continue to execute against our Vision 2025 to bring them novel medicines.
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
- Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
- Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
- Cytokinetics to Participate in Upcoming Investor Conferences